Heart failure & cardiomyopathies
Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure
Authors' conclusion
In IRONMAN, FDI exerted similar reductions in cardiovascular and noncardiovascular hospitalizations
Study context
- Population
- Patients with HF, LVEF ≤45%, and transferrin saturation <20% or serum ferritin <100 μg/L
- Participants
- 568 vs 569
- Comparison
- IV ferric derisomaltose vs usual care
- Ferric derisomaltose (FDI)n = 568
- Usual caren = 569reference
- Primary endpoint
- Adjudicated causes of unplanned hospitalizations and deaths
- Follow-up
- Median 2.7 years (Q1-Q3: 1.8-3.6 years)
Primary result
As reported in the abstract
Unplanned hospitalizations (recurrent events)
FDI vs Usual careRelative risk (rate ratio) (95% CI)P value
All unplanned hospitalizations
0.83(0.71–0.97)
P = 0.02CV hospitalizations
0.83(0.69–1.01)
non-CV hospitalizations
0.83(0.67–1.03)
HF hospitalizations
0.78(0.60–1.00)
Respiratory disease hospitalizations
0.70(0.53–0.97)
Infection hospitalizations
0.82(0.66–1.03)
- HF main cause of hospitalizations
- 26%
- HF contributed to or complicated a further share of hospitalizations
- 12%
- Infection caused or contributed to all hospitalizations
- 38%
- Infection caused or contributed to HF hospitalizations
- 27%
Further findings
CV and all-cause mortality
- Patterns similar for FDI and usual care
Original publication
Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure. J Am Coll Cardiol. Published 29 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →